BR112017002268A2 - sal de derivado de piridina monocíclica e cristal do mesmo - Google Patents
sal de derivado de piridina monocíclica e cristal do mesmoInfo
- Publication number
- BR112017002268A2 BR112017002268A2 BR112017002268A BR112017002268A BR112017002268A2 BR 112017002268 A2 BR112017002268 A2 BR 112017002268A2 BR 112017002268 A BR112017002268 A BR 112017002268A BR 112017002268 A BR112017002268 A BR 112017002268A BR 112017002268 A2 BR112017002268 A2 BR 112017002268A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystal
- pyridine derivative
- derivative salt
- monocyclic pyridine
- monocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
a presente invenção proporciona sais consistindo em um ácido organocarboxílico selecionado a partir do grupo consistido por ácido succínico e ácido maleico e um composto representado pela fórmula (i); e cristais dos mesmos, que podem ser usados como materiais em bruto para produtos farmacêuticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014166118 | 2014-08-18 | ||
JP2014-166118 | 2014-08-18 | ||
PCT/JP2015/073047 WO2016027781A1 (ja) | 2014-08-18 | 2015-08-17 | 単環ピリジン誘導体の塩およびその結晶 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017002268A2 true BR112017002268A2 (pt) | 2017-11-21 |
BR112017002268B1 BR112017002268B1 (pt) | 2022-11-08 |
Family
ID=55350725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017002268-0A BR112017002268B1 (pt) | 2014-08-18 | 2015-08-17 | Sal de derivado de piridina monocíclica e cristal do mesmo |
Country Status (14)
Country | Link |
---|---|
US (1) | US9951047B2 (pt) |
EP (1) | EP3184520B1 (pt) |
JP (1) | JP5925978B1 (pt) |
KR (1) | KR102344105B1 (pt) |
CN (1) | CN106660997B (pt) |
AU (1) | AU2015304465B2 (pt) |
BR (1) | BR112017002268B1 (pt) |
CA (1) | CA2956270C (pt) |
ES (1) | ES2914072T3 (pt) |
IL (1) | IL250290B (pt) |
MX (1) | MX369646B (pt) |
RU (1) | RU2658821C1 (pt) |
SG (1) | SG11201700703XA (pt) |
WO (1) | WO2016027781A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115177619A (zh) * | 2015-12-17 | 2022-10-14 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
US20200297711A1 (en) * | 2017-10-12 | 2020-09-24 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising fgfr selective tyrosine kinase inhibitor |
EP3777860A4 (en) * | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA |
JPWO2021210636A1 (pt) | 2020-04-17 | 2021-10-21 | ||
AU2021315234A1 (en) | 2020-07-31 | 2023-01-19 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
US20230330081A1 (en) | 2020-10-28 | 2023-10-19 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
IL310338A (en) | 2021-08-31 | 2024-03-01 | Eisai R&D Man Co Ltd | Production method for a synthetic intermediate of a monocyclic pyridine derivative |
JP7315806B1 (ja) | 2021-08-31 | 2023-07-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 単環ピリジン誘導体の製造方法 |
WO2023174400A1 (zh) * | 2022-03-18 | 2023-09-21 | 上海润石医药科技有限公司 | 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10006139A1 (de) | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2004020434A1 (ja) | 2002-08-30 | 2004-03-11 | Eisai Co., Ltd. | 含窒素芳香環誘導体 |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
BRPI0409366A (pt) | 2003-04-10 | 2006-04-25 | Hoffmann La Roche | compostos de pirimido |
US20050256154A1 (en) | 2004-05-04 | 2005-11-17 | Kin-Chun Luk | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
FR2883286B1 (fr) | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
KR101368519B1 (ko) | 2005-05-23 | 2014-02-27 | 노파르티스 아게 | 결정형 및 기타 형태의 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락트산염 |
SMP200800041B (it) | 2005-12-21 | 2009-07-14 | Novartis Ag | Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori |
TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP1891955A1 (en) | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
PL2121687T3 (pl) | 2006-12-22 | 2016-03-31 | Astex Therapeutics Ltd | Pochodne amin tricyklicznych jako inhibitory białkowej kinazy tyrozynowej |
JP5442448B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | Fgfrインヒビターとしての二環式ヘテロ環式化合物 |
EP2158470A1 (en) | 2007-06-25 | 2010-03-03 | Qinetiq Limited | Preconcentrator device incorporating a polymer of intrinsic microporosity |
WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
WO2009056886A1 (en) | 2007-11-01 | 2009-05-07 | Astrazeneca Ab | Pyrimidine derivatives and their use as modulators of fgfr activity |
CL2008003675A1 (es) | 2007-12-13 | 2009-03-20 | Wyeth Corp | Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide. |
CA2725185C (en) | 2008-05-23 | 2016-10-25 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
JP2011524888A (ja) | 2008-06-19 | 2011-09-08 | アストラゼネカ アクチボラグ | ピラゾール化合物436 |
WO2010078427A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted pyrazolo [3, 4-b] pyridine compounds |
US8273754B2 (en) | 2008-12-30 | 2012-09-25 | Arqule, Inc. | Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds |
WO2010078421A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds |
US9002427B2 (en) | 2009-03-30 | 2015-04-07 | Lifewave Biomedical, Inc. | Apparatus and method for continuous noninvasive measurement of respiratory function and events |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
FR2947546B1 (fr) | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
ES2561659T3 (es) | 2009-08-07 | 2016-02-29 | Chugai Seiyaku Kabushiki Kaisha | Derivados de aminopirazol |
IN2012DN03180A (pt) | 2009-10-30 | 2015-09-25 | Novartis Ag | |
AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
CA2841886C (en) | 2011-07-19 | 2016-08-16 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
ES2516392T3 (es) | 2012-01-19 | 2014-10-30 | Taiho Pharmaceutical Co., Ltd. | Compuesto de alquinilbenceno 3,5-disustituido y sal del mismo |
JP5343177B1 (ja) | 2012-02-28 | 2013-11-13 | アステラス製薬株式会社 | 含窒素芳香族へテロ環化合物 |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
UA117347C2 (uk) | 2012-06-13 | 2018-07-25 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
WO2014007369A1 (ja) | 2012-07-05 | 2014-01-09 | 独立行政法人国立がん研究センター | Fgfr2融合遺伝子 |
CN109627239B (zh) | 2012-07-11 | 2021-10-12 | 缆图药品公司 | 成纤维细胞生长因子受体的抑制剂 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
WO2014048878A1 (en) | 2012-09-26 | 2014-04-03 | Evotec (Uk) Ltd. | Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia |
US10689705B2 (en) | 2012-09-27 | 2020-06-23 | Chugai Seiyaku Kabushiki Kaisha | FGFR3 fusion gene and pharmaceutical drug targeting same |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
TWI628176B (zh) | 2013-04-04 | 2018-07-01 | 奧利安公司 | 蛋白質激酶抑制劑 |
-
2015
- 2015-08-17 RU RU2017103439A patent/RU2658821C1/ru active
- 2015-08-17 CA CA2956270A patent/CA2956270C/en active Active
- 2015-08-17 KR KR1020177002791A patent/KR102344105B1/ko active IP Right Grant
- 2015-08-17 AU AU2015304465A patent/AU2015304465B2/en active Active
- 2015-08-17 JP JP2015560425A patent/JP5925978B1/ja active Active
- 2015-08-17 MX MX2017001624A patent/MX369646B/es active IP Right Grant
- 2015-08-17 WO PCT/JP2015/073047 patent/WO2016027781A1/ja active Application Filing
- 2015-08-17 EP EP15834302.0A patent/EP3184520B1/en active Active
- 2015-08-17 ES ES15834302T patent/ES2914072T3/es active Active
- 2015-08-17 BR BR112017002268-0A patent/BR112017002268B1/pt active IP Right Grant
- 2015-08-17 CN CN201580042132.3A patent/CN106660997B/zh active Active
- 2015-08-17 SG SG11201700703XA patent/SG11201700703XA/en unknown
- 2015-08-17 US US15/500,429 patent/US9951047B2/en active Active
-
2017
- 2017-01-25 IL IL250290A patent/IL250290B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
SG11201700703XA (en) | 2017-03-30 |
CA2956270C (en) | 2022-08-09 |
EP3184520A1 (en) | 2017-06-28 |
RU2658821C1 (ru) | 2018-06-25 |
CN106660997A (zh) | 2017-05-10 |
IL250290B (en) | 2020-06-30 |
BR112017002268B1 (pt) | 2022-11-08 |
CA2956270A1 (en) | 2016-02-25 |
US20170217935A1 (en) | 2017-08-03 |
JPWO2016027781A1 (ja) | 2017-04-27 |
KR102344105B1 (ko) | 2021-12-29 |
KR20170035927A (ko) | 2017-03-31 |
AU2015304465A1 (en) | 2017-02-23 |
MX369646B (es) | 2019-11-15 |
US9951047B2 (en) | 2018-04-24 |
WO2016027781A1 (ja) | 2016-02-25 |
MX2017001624A (es) | 2017-04-27 |
CN106660997B (zh) | 2019-05-21 |
AU2015304465B2 (en) | 2019-05-09 |
IL250290A0 (en) | 2017-03-30 |
EP3184520B1 (en) | 2022-03-23 |
JP5925978B1 (ja) | 2016-05-25 |
ES2914072T3 (es) | 2022-06-07 |
EP3184520A4 (en) | 2018-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017002268A2 (pt) | sal de derivado de piridina monocíclica e cristal do mesmo | |
BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
BR112017006809A2 (pt) | compostos de ácido carboxílico úteis para inibir a prostaglandina e2 sintase-1 microssômica | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112017010354A2 (pt) | compostos de triazolopirimidina e usos dos mesmos | |
CU20170116A7 (es) | Compuestos cíclicos terapéuticos como inmunomoduladores | |
BR112017002827A2 (pt) | derivado de quinolina altamente puro e método para produção do mesmo | |
BR112016023853A2 (pt) | composto, composição, método para controlar a vegetação indesejável e uso de um composto | |
BR112017007368A2 (pt) | "composto, composição, método para o controle de vegetação indesejada e utilização de um composto" | |
MD4807B1 (ro) | Derivaţi de pirimidiniloxi-benzen utilizaţi ca erbicide | |
BR112014027236A2 (pt) | pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas | |
EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
BR112017000418A2 (pt) | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina | |
BR112017006240A2 (pt) | novos compostos | |
BR112013011593A2 (pt) | cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo | |
BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
BR112017009470A2 (pt) | síntese de copanlisib e seu sal de di-hidrocloreto. | |
BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm | |
BR112017007014A2 (pt) | derivados de benzotiofenila substituídos como agonistas do gpr40 para o tratamento de diabetes tipo ii | |
CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
BR112017009471A2 (pt) | síntese de copanlisib e seu sal de di-hidrocloreto. | |
EA201300946A1 (ru) | Асимметричные мочевины и их медицинское применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2015, OBSERVADAS AS CONDICOES LEGAIS |